The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
Author(s)
Type
Journal Article
Abstract
The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition. The definition and diagnosis of disease types continues to be based on multiple clinicopathologic parameters, but with refinement of diagnostic criteria and emphasis on therapeutically and/or prognostically actionable biomarkers. While a genetic basis for defining diseases is sought where possible, the classification strives to keep practical worldwide applicability in perspective. The result is an enhanced, contemporary, evidence-based classification of myeloid and histiocytic/dendritic neoplasms, rooted in molecular biology and an organizational structure that permits future scalability as new discoveries continue to inexorably inform future editions.
Date Issued
2022-06-22
Date Acceptance
2022-05-20
Citation
Leukemia, 2022, 36 (7), pp.1703-1719
ISSN
0887-6924
Publisher
Springer Nature [academic journals on nature.com]
Start Page
1703
End Page
1719
Journal / Book Title
Leukemia
Volume
36
Issue
7
Copyright Statement
© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Identifier
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000814462100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
CHRONIC MYELOMONOCYTIC LEUKEMIA
CLONAL HEMATOPOIESIS
DIAGNOSIS
ESSENTIAL THROMBOCYTHEMIA
FLOW-CYTOMETRY
Hematology
LANDSCAPE
Life Sciences & Biomedicine
LYMPHOMA
Oncology
PROGNOSTIC-SIGNIFICANCE
ROSAI-DORFMAN DISEASE
SARCOMA
Science & Technology
Publication Status
Published
Date Publish Online
2022-06-22